At EBMT 2025, Dr. Rémy Duléry (Dana-Farber Cancer Institute) presented highly promising data on novel immunotherapeutic strategies for relapsed/refractory AML. While CD123-targeted CAR T-cell therapy has shown limited long-term survival in this population, a new engineered approach using IL-12-enhanced CAR NK cells may offer a safer, more effective alternative.
These modified NK cells not only demonstrated enhanced cytotoxicity and immune activation across AML cell lines, but also present a potential “off-the-shelf” solution for patients with poor prognosis. Current research is focused on in vivo persistence, expansion, and translation into clinical settings.
Early findings suggest these platforms may benefit not only AML but also other hematologic malignancies and solid tumors.
Thanks to Dr. Dulery for sharing this exciting research.
For more details, visit: https://lnkd.in/debkhSbb
